Programmable gene modulation networks for Parkinson's disease using nanotechnology enabled CRISPR/Cas brain delivery

Area of Science:

• Neuroscience
• Genetics
• Biotechnology

Background:

• Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by α-synuclein aggregation, mitochondrial dysfunction, impaired proteostasis, and neuroinflammation.
• Current symptomatic treatments for PD do not prevent disease progression.

Purpose of the Study:

• To introduce Programmable Gene Modulation Networks (PGMNs) as a systems-level framework for precision intervention in Parkinson's disease.
• To evaluate advanced CRISPR/Cas technologies and nanotechnology-enabled brain delivery systems for PD therapy.

Main Methods:

• Review of advanced CRISPR modalities (CRISPR interference, activation, base editing, prime editing, epigenetic editing) for targeted gene modulation.
• Discussion of non-viral nanocarrier platforms (lipid nanoparticles, polymeric systems, exosome-mimetic vesicles) for overcoming blood-brain barrier limitations and enhancing brain-specific delivery.

Main Results:

• CRISPR technologies offer reversible and targeted modulation of PD-relevant gene networks.
• Nanocarrier platforms show potential for efficient and brain-specific delivery of gene-editing tools.

Conclusions:

• Integrating molecular network biology, programmable gene regulation, and nanotechnology provides a roadmap for next-generation, disease-modifying Parkinson's disease therapies.
• Addressing translational challenges is crucial for clinical implementation of these advanced therapeutic strategies.